Lyell Immunopharma Inc
Ownership
Ownership Structure
Who owns Lyell Immunopharma Inc (LYEL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 40.2% of the shares are freely tradable; institutional investors hold 57.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARCH VENTURE CORP | 13.21 | 3,247,162 | +0.0 | 06/30/2026 |
| GSK PLC | 6.15 | 1,512,659 | +0.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.20 | 786,774 | +9.6 | 06/30/2026 |
| Orland Properties Ltd | 3.07 | 754,698 | +0.0 | 06/30/2026 |
| BlackRock Inc | 2.95 | 724,342 | +277.6 | 06/30/2026 |
| Almitas Capital LLC | 2.36 | 581,407 | +0.6 | 06/30/2026 |
| Foresite Capital Management V, LLC | 1.94 | 476,386 | -0.1 | 06/30/2026 |
| Millennium Management LLC | 1.49 | 367,473 | -19.9 | 06/30/2026 |
| Opaleye Management Inc | 1.40 | 344,025 | +334.9 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.46 | 604,461 | +0.0 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| ARCH Venture Partners IX, LLC | 10% Owner | 3,747,790 | 53,593,397 $ | Nov 4, 2026 | indirect |
| ARCH Venture Fund XIII, L.P. | 10% Owner | 3,747,790 | 53,593,397 $ | Nov 4, 2026 | indirect |
| Seely Lynn | President and CEO | 63,354 | 905,962 $ | Nov 10, 2026 | direct |
| Shook David | Chief Medical Officer | 20,423 | 292,049 $ | Sep 10, 2026 | direct |
| Aguirre Jarrad Mattieu | Chief Medical Officer | 19,857 | 283,955 $ | Oct 12, 2026 | direct |
| Hill Stephen J. | Chief Operating Officer | 16,728 | 239,210 $ | Nov 10, 2026 | direct |
| Lee Gary K. | Chief Scientific Officer | 16,091 | 230,101 $ | Nov 10, 2026 | direct |
| Bulis Veronica Sanchez | VP, Corporate Controller | 14,383 | 205,677 $ | Nov 10, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 416 | 15.93 | 6,627 |
| Nov 10, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 129 | 15.93 | 2,055 |
| Nov 10, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 88 | 15.93 | 1,402 |
| Nov 10, 2026 | Seely Lynn | President and CEO | Sell | 545 | 15.93 | 8,682 |
| Nov 4, 2026 | ARCH Venture Partners IX, LLC | 10% Owner | Buy | 2,321,262 | 10.77 | 24,999,992 |
| Nov 4, 2026 | ARCH Venture Fund XIII, L.P. | 10% Owner | Buy | 2,321,262 | 10.77 | 24,999,992 |
| Oct 12, 2026 | Aguirre Jarrad Mattieu | Chief Medical Officer | Sell | 422 | 8.63 | 3,642 |
| Sep 10, 2026 | Shook David | Chief Medical Officer | Sell | 500 | 12.70 | 6,350 |
| Aug 21, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 1,457 | 15.54 | 22,642 |
| Aug 21, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 989 | 15.54 | 15,369 |
| Aug 21, 2026 | Seely Lynn | President and CEO | Sell | 9,589 | 15.54 | 149,013 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.